PARIS--(BUSINESS WIRE)--GenSight Biologics S.A. (GenSight), a clinical-stage biotechnology company discovering and developing novel therapies for mitochondrial and neurodegenerative diseases of the eye, and in the future, of the central nervous system, announced the appointments of Thomas Gidoin as Chief Financial Officer and Michael Wyzga as Independent Director. In this role, Mr. Gidoin is responsible for the company’s corporate and financial development strategies and operations, and will report to Dr. Bernard Gilly, Chief Executive Officer and Chairman of GenSight.
Help employers find you! Check out all the jobs and post your resume.
